Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference.

@article{Lublin1996ManagementOP,
  title={Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference.},
  author={Fred D. Lublin and John N. Whitaker and Benjamin H. Eidelman and Aaron E. Miller and Barry G. W. Arnason and Jack Burks},
  journal={Neurology},
  year={1996},
  volume={46 1},
  pages={12-8}
}
Results of a double-blind, placebo-controlled study in ambulatory patients with relapsing-remitting MS showed that interferon beta-1b reduced the rate of exacerbations by one-third compared with placebo and limited new disease activity in the brain as evidenced by MRI. Interferon beta-1b, administered subcutaneously at a dosage of 0.25 mg (8 million IU) every other day is indicated for the treatment of ambulatory patients with relapsing-remitting MS. Interferon beta-1b may help a wider range of… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

Similar Papers

Loading similar papers…